Levofloxacin Injection
Product Images NDC 63323-355

6 FDA label images from Fresenius Kabi Usa, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Levofloxacin (NDC 63323-355). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemstruct (Lev1v 0001 01)

Chemstruct (Lev1v 0001 01)
Chemical structure of Levofloxacin showing its molecular components including a fluorine atom, methyl group, and carboxylic acid functional group, along with a half molecule of water (H2O) indicating a hydrate form.*
FDA Label Image

Figure 2 (Lev1v 0001 02)

Figure 2 (Lev1v 0001 02)
A line graph depicting mean Levofloxacin plasma concentration (mcg/mL) over time (hours) comparing 750 mg tablet oral administration and 750 mg intravenous infusion given over 90 minutes. The chart shows plasma concentration on the y-axis and time up to 36 hours on the x-axis, illustrating concentration changes after dosing by each route.*
FDA Label Image

Figure 3 (Lev1v 0001 03)

Figure 3 (Lev1v 0001 03)
A line graph titled 'Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg' comparing plasma concentrations (mcg/mL) over time (hours) for 500 mg doses administered orally as tablets and intravenously (IV). The graph shows peak concentration occurring earlier with IV administration and higher initial plasma levels compared to oral tablets, with concentrations decreasing over 36 hours.*
FDA Label Image

Logo (Lev1v 0001 04)

FDA Label Image

Bag (Lev1v 0001 05)

Bag (Lev1v 0001 05)
Levofloxacin 250 mg in 50 mL (5 mg/mL) intravenous injection in 5% dextrose solution. The label specifies single-use for intravenous infusion and includes dispensing instructions and warnings. Manufactured for Fresenius Kabi USA, LLC, Lake Zurich, IL. The product is made in Norway and does not contain natural rubber latex in its closure.*
FDA Label Image

Overwrap (Lev1v 0001 06)

Overwrap (Lev1v 0001 06)
Levofloxacin 5 mg/mL injection in 5% dextrose, 250 mg in 50 mL single-use intravenous infusion vial. The label indicates storage instructions, usage directions for infusion over 60 minutes, and cautions about temperature and use. Manufactured by Fresenius Kabi USA, LLC, made in Norway.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.